<p>/PRNewswire/ - 德沃尼健康集团公司（&#34; <strong>Devonian</strong>&#34; 或 &#34; <strong>公司</strong>&#34;）（TSXV: GSD）（OTCQB: DVHGF）是一家专注于开发独特解决方案以应对纤维炎症疾病的临床阶段公司，欣然宣布已任命丹尼斯·图尔平（Dennis Turpin）为公司首席财务官，任命即日生效。图尔平先生目前担任公司董事会成员，并将继续留任。在担任首席财务官之前，他还曾担任审计委员会主席，该职位将由皮埃尔·拉贝（Pierre Labbé）接任。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg"/></p>
<p>图尔平先生是一位经验丰富的职业高管和注册专业会计师（CPA），在财务、资本市场交易、业务发展以及并购方面拥有超过 25 年的丰富经验，其中大部分时间在生物制药行业工作。</p>
<p><em>&#34;我很高兴欢迎丹尼斯，并相信他将帮助加强我们的管理方法，丰富我们的视角，提升我们的集体专业知识，并指导德沃尼的发展。&#34;首席执行官安德烈·P·布莱特（André P. Boulet）博士表示。</em></p>
<p>图尔平先生将接替维克托里亚·克拉斯特瓦（Viktoria Krasteva），后者将继续留在公司，协助确保在 2026 年 2 月 27 日之前的顺利过渡。董事会感谢克拉斯特瓦女士对公司的贡献，并祝愿她在未来的事业中一切顺利。</p>
<p>共向图尔平先生授予 25,000 股股票期权。这些期权立即生效，行使价格为 11.50 美元，行使期限为授予日期后的 10 年。</p>
<p><strong>期权授予更新</strong></p>
<p>公司还希望更正于 2025 年 12 月 19 日发布的新闻稿，关于向公司董事和顾问授予 2,948,056 股股票期权，以及向员工授予 385,950 股股票期权和向一名研发顾问授予 100,000 股股票期权。根据股票期权计划的条款，股票期权的行使价格不得低于授予日期前一个交易日收盘时普通股的市场价格。因此，之前披露的行使价格 0.18 美元已更正为 0.19 美元，这是授予日期前一个交易日收盘时的适用市场价格。所有其他股票期权授予的条款保持不变。根据公司于 2026 年 1 月 22 日完成的股份合并，每 60 股合并前普通股对应 1 股合并后普通股，上述股票期权已根据公司股票期权计划的条款自动调整。因此，每 60 股合并前期权现在代表 1 股合并后期权，修正后的行使价格 0.19 美元已调整为合并后每股 11.40 美元。期权数量已向下取整至下一个最小整数，以便持有人在行使时仅能购买整股普通股。</p>
<p><strong>关于德沃尼</strong></p>
<p>德沃尼健康集团公司是一家临床阶段制药公司，专注于开发针对各种自身免疫性纤维炎症疾病的药物，采用新颖的治疗方法以满足未满足的医疗需求。德沃尼的核心战略是开发用于治疗纤维炎症自身免疫疾病的处方药，包括但不限于特应性皮炎、放射性皮炎和溃疡性结肠炎。</p>
<p>德沃尼还参与开发高价值的药妆产品，利用与其制药产品相同的专有方法。德沃尼还拥有一家商业化子公司 Altius Healthcare LP，专注于在加拿大销售处方药，获得品牌制药公司的许可。</p>
<p>德沃尼健康集团公司成立于 2015 年，总部位于加拿大魁北克，拥有一座先进的提取设施。德沃尼在多伦多证券交易所创业板（&#34; <strong>交易所</strong>&#34;）（ <strong>TSXV: GSD</strong>）上市，并目前在 OTCQB 创业市场（ <strong>OTCQB: DVHGF</strong>）报价。</p>
<p>欲了解更多信息，请访问 www.groupedevonian.com。</p>
<p><strong>关于前瞻性声明的警示说明</strong> 本新闻稿中包含的所有声明，除了历史事实声明外，包括上述&#34;关于德沃尼&#34;段落，均构成某些证券法意义上的&#34;前瞻性信息&#34;或&#34;前瞻性声明&#34;（统称为&#34;前瞻性声明&#34;），并基于本新闻稿发布时的预期、估计和预测。这些前瞻性声明可能通过使用诸如&#34;打算&#34;、&#34;相信&#34;、&#34;期望&#34;或这些词和短语的变体（包括否定和语法变体）来识别，或表明某些行动、事件或结果&#34;可能&#34;、&#34;可以&#34;、&#34;将&#34;或&#34;会&#34;被采取、发生或实现。</p>
<p>前瞻性声明必然基于许多估计和假设，尽管公司在作出这些声明时认为这些估计和假设是合理的，但本质上仍然受到重大商业、经济和竞争不确定性及偶发事件的影响。这些估计和假设可能被证明是错误的。许多不确定性和偶发事件可能直接或间接影响实际结果，并可能导致实际结果与任何前瞻性声明中所表达或暗示的结果存在重大差异。不能保证这些假设会被证明是正确的，也不能保证前瞻性声明会被证明是准确的，因为实际结果和未来事件可能与这些声明中预期的结果存在重大差异。</p>
<p>由于其本质，前瞻性声明涉及固有的风险和不确定性，包括一般性和特定性风险，存在估计、预测、展望和其他前瞻性声明未能实现或假设未能反映未来经验的风险。前瞻性声明的目的是提供有关管理层对未来的期望和计划的信息。读者应谨慎对待这些前瞻性声明，不应过度依赖，因为许多重要的风险因素和未来事件可能导致实际结果与这些前瞻性声明中表达的信念、计划、目标、期望、预期、估计、假设和意图存在重大差异。本新闻稿中所作的所有前瞻性声明均受到这些警示性声明以及我们在加拿大相关证券监管机构的其他文件中所作声明的限制。公司不承担更新或修订任何前瞻性声明的意图或义务，也不解释后续实际事件与这些前瞻性声明之间的任何重大差异，除非适用法律要求。</p>
<p><em>交易所及其监管服务提供者（根据交易所政策定义的术语）对本公告的充分性或准确性不承担责任。</em></p>
<p>来源：Devonian Health Group Inc.</p>

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

DNLI

AMPGW

动态生物技术与基因组 ETF - Invesco

<p>Devonian Health Group Inc. 已任命 Dennis Turpin 为首席财务官，立即生效。Turpin 是一位在生物制药行业拥有超过 25 年经验的资深高管，他还将继续担任董事会成员。他接替 Viktoria Krasteva，后者将在过渡期间协助，直到 2026 年 2 月。此外，Turpin 获得了 25,000 个股票期权，行使价格为 11.50 美元。公司对之前的股票期权授予进行了修正，将行使价格从 0.18 美元调整为 0.19 美元，合并后的期权现在反映的价格为 11.40 美元</p>

<p>, /PRNewswire/ - Devonian Health Group Inc. (&#34; <strong>Devonian</strong>&#34; or the &#34; <strong>Company</strong>&#34;) (TSXV: GSD) (OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, is pleased to announce that it has appointed Dennis Turpin as Chief Financial Officer of the Company, effective today. Mr. Turpin currently serves and will remain on the Board of Directors of the Company. Before his appointment as Chief Financial Officer, he also served as Chair of the Audit Committee, a role that will now be assumed by Mr. Pierre Labbé.</p>
<div class="lb-trans"><p>/PRNewswire/ - 德沃尼健康集团公司（&#34; <strong>Devonian</strong>&#34; 或 &#34; <strong>公司</strong>&#34;）（TSXV: GSD）（OTCQB: DVHGF）是一家专注于开发独特解决方案以应对纤维炎症疾病的临床阶段公司，欣然宣布已任命丹尼斯·图尔平（Dennis Turpin）为公司首席财务官，任命即日生效。图尔平先生目前担任公司董事会成员，并将继续留任。在担任首席财务官之前，他还曾担任审计委员会主席，该职位将由皮埃尔·拉贝（Pierre Labbé）接任。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg" alt="" original-src="https://mma.prnewswire.com/media/2874053/Devonian_Health_Group_Inc__DEVONIAN_APPOINTS_DENNIS_TURPIN_AS_CH.jpg"/></p>
<p>Mr. Turpin is a seasoned professional executive and chartered professional accountant (CPA) with significant experience in finance, capital markets transactions, business development as well as mergers and acquisitions, over 25 years of which have been in the biopharmaceutical industry.</p>
<div class="lb-trans"><p>图尔平先生是一位经验丰富的职业高管和注册专业会计师（CPA），在财务、资本市场交易、业务发展以及并购方面拥有超过 25 年的丰富经验，其中大部分时间在生物制药行业工作。</p>
</div><p><em>&#34;I am pleased to welcome Dennis and confident that he will help strengthen our management approach, diversify our perspectives, enhance our collective expertise, and help guide the development of Devonian.&#34; said Dr. André P. Boulet, PhD, Chief Executive Officer.</em></p>
<div class="lb-trans"><p><em>&#34;我很高兴欢迎丹尼斯，并相信他将帮助加强我们的管理方法，丰富我们的视角，提升我们的集体专业知识，并指导德沃尼的发展。&#34;首席执行官安德烈·P·布莱特（André P. Boulet）博士表示。</em></p>
</div><p>Mr. Turpin will replace Viktoria Krasteva, who will remain with the Company and assist ensuring a smooth transition until February27, 2026. The Board would like to thank Ms. Krasteva for her contributions to the Company and wishes her well in her future endeavors.</p>
<div class="lb-trans"><p>图尔平先生将接替维克托里亚·克拉斯特瓦（Viktoria Krasteva），后者将继续留在公司，协助确保在 2026 年 2 月 27 日之前的顺利过渡。董事会感谢克拉斯特瓦女士对公司的贡献，并祝愿她在未来的事业中一切顺利。</p>
</div><p>A total of 25,000 stock options were granted to Mr. Turpin. These options are vesting immediately and are exercisable at a price of $11.50, for a period of 10 years following the grant date.</p>
<div class="lb-trans"><p>共向图尔平先生授予 25,000 股股票期权。这些期权立即生效，行使价格为 11.50 美元，行使期限为授予日期后的 10 年。</p>
</div><p><strong>Options Grant Updates</strong></p>
<div class="lb-trans"><p><strong>期权授予更新</strong></p>
</div><p>The Company also wishes to correct the press release issued on December 19, 2025, regarding the granting of 2,948,056 stock options to directors and a consultant of the Company, as well as the additional grants of 385,950 stock options to employees and 100,000 stock options to a research and development consultant. Pursuant to the terms of the stock option plan, the exercise price of stock options may not be set below the market price of the common shares at the close of trading on the exchange on the trading day immediately preceding the grant date. Accordingly, the exercise price previously disclosed as $0.18 has been corrected to $0.19, being the applicable market price at the close of trading on the exchange on the trading day immediately preceding the grant date. All other terms of the stock option grants remain unchanged. Further to the share consolidation completed by the Company on January 22, 2026, on the basis of one post‑consolidation common share for every 60 pre‑consolidation common shares, the stock options described above have been automatically adjusted in accordance with the terms of the Company's stock option plan. As a result, each block of 60 pre‑consolidation options now represents one post‑consolidation option, and the corrected exercise price of $0.19 per share has been adjusted to $11.40 per share on a post‑consolidation basis. The number of options has been rounded down to the next lowest whole in order to allow the holder to purchase only a whole number of common shares upon exercise.</p>
<div class="lb-trans"><p>公司还希望更正于 2025 年 12 月 19 日发布的新闻稿，关于向公司董事和顾问授予 2,948,056 股股票期权，以及向员工授予 385,950 股股票期权和向一名研发顾问授予 100,000 股股票期权。根据股票期权计划的条款，股票期权的行使价格不得低于授予日期前一个交易日收盘时普通股的市场价格。因此，之前披露的行使价格 0.18 美元已更正为 0.19 美元，这是授予日期前一个交易日收盘时的适用市场价格。所有其他股票期权授予的条款保持不变。根据公司于 2026 年 1 月 22 日完成的股份合并，每 60 股合并前普通股对应 1 股合并后普通股，上述股票期权已根据公司股票期权计划的条款自动调整。因此，每 60 股合并前期权现在代表 1 股合并后期权，修正后的行使价格 0.19 美元已调整为合并后每股 11.40 美元。期权数量已向下取整至下一个最小整数，以便持有人在行使时仅能购买整股普通股。</p>
</div><p><strong>About Devonian</strong></p>
<div class="lb-trans"><p><strong>关于德沃尼</strong></p>
</div><p>Devonian Health Group Inc. is a clinical stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory disease with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of fibroinflammatory autoimmune diseases including but not limited to atopic dermatitis, radiodermatitis and ulcerative colitis.</p>
<div class="lb-trans"><p>德沃尼健康集团公司是一家临床阶段制药公司，专注于开发针对各种自身免疫性纤维炎症疾病的药物，采用新颖的治疗方法以满足未满足的医疗需求。德沃尼的核心战略是开发用于治疗纤维炎症自身免疫疾病的处方药，包括但不限于特应性皮炎、放射性皮炎和溃疡性结肠炎。</p>
</div><p>Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licenses from brand name pharmaceutical companies.</p>
<div class="lb-trans"><p>德沃尼还参与开发高价值的药妆产品，利用与其制药产品相同的专有方法。德沃尼还拥有一家商业化子公司 Altius Healthcare LP，专注于在加拿大销售处方药，获得品牌制药公司的许可。</p>
</div><p>Devonian Health Group Inc. was incorporated in 2015 and is headquartered in Quebec, Canada where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange (the &#34; <strong>Exchange</strong>&#34;) ( <strong>TSXV: GSD</strong>) and currently quoted on the OTCQB Venture Market ( <strong>OTCQB: DVHGF</strong>).</p>
<div class="lb-trans"><p>德沃尼健康集团公司成立于 2015 年，总部位于加拿大魁北克，拥有一座先进的提取设施。德沃尼在多伦多证券交易所创业板（&#34; <strong>交易所</strong>&#34;）（ <strong>TSXV: GSD</strong>）上市，并目前在 OTCQB 创业市场（ <strong>OTCQB: DVHGF</strong>）报价。</p>
</div><p>For more information, visit www.groupedevonian.com.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.groupedevonian.com。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong> All statements, other than statements of historical fact, contained in this press release including, the above &#34;About Devonian&#34; paragraph, all of which essentially describes the Company's outlook, constitute &#34;forward-looking information&#34; or &#34;forward-looking statements&#34; within the meaning of certain securities laws (collectively, &#34;forward-looking statements&#34;), and are based on expectations, estimates and projections as of the time of this press release. Such forward-looking statements may be identified by the use of words such as &#34;intends&#34;, &#34;believes&#34;, &#34;expects&#34;, or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results &#34;may&#34;, &#34;could&#34;, &#34;would&#34;, or &#34;will&#34; be taken, occur or be achieved.</p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong> 本新闻稿中包含的所有声明，除了历史事实声明外，包括上述&#34;关于德沃尼&#34;段落，均构成某些证券法意义上的&#34;前瞻性信息&#34;或&#34;前瞻性声明&#34;（统称为&#34;前瞻性声明&#34;），并基于本新闻稿发布时的预期、估计和预测。这些前瞻性声明可能通过使用诸如&#34;打算&#34;、&#34;相信&#34;、&#34;期望&#34;或这些词和短语的变体（包括否定和语法变体）来识别，或表明某些行动、事件或结果&#34;可能&#34;、&#34;可以&#34;、&#34;将&#34;或&#34;会&#34;被采取、发生或实现。</p>
</div><p>Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company as of the time of such statements, are inherently subject to significant business, economic and competitive uncertainties and contingencies. These estimates and assumptions may prove to be incorrect. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements. There can be no assurance that these assumptions will prove to be correct and there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.</p>
<div class="lb-trans"><p>前瞻性声明必然基于许多估计和假设，尽管公司在作出这些声明时认为这些估计和假设是合理的，但本质上仍然受到重大商业、经济和竞争不确定性及偶发事件的影响。这些估计和假设可能被证明是错误的。许多不确定性和偶发事件可能直接或间接影响实际结果，并可能导致实际结果与任何前瞻性声明中所表达或暗示的结果存在重大差异。不能保证这些假设会被证明是正确的，也不能保证前瞻性声明会被证明是准确的，因为实际结果和未来事件可能与这些声明中预期的结果存在重大差异。</p>
</div><p>By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. Readers are cautioned not to place undue reliance on these forward-looking statements as a number of important risk factors and future events could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. All of the forward-looking statements made in this press release are qualified by these cautionary statements and those made in our other filings with the applicable securities regulators of Canada. The Company disclaims any intention or obligation to update or revise any forward-looking statements or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law.</p>
<div class="lb-trans"><p>由于其本质，前瞻性声明涉及固有的风险和不确定性，包括一般性和特定性风险，存在估计、预测、展望和其他前瞻性声明未能实现或假设未能反映未来经验的风险。前瞻性声明的目的是提供有关管理层对未来的期望和计划的信息。读者应谨慎对待这些前瞻性声明，不应过度依赖，因为许多重要的风险因素和未来事件可能导致实际结果与这些前瞻性声明中表达的信念、计划、目标、期望、预期、估计、假设和意图存在重大差异。本新闻稿中所作的所有前瞻性声明均受到这些警示性声明以及我们在加拿大相关证券监管机构的其他文件中所作声明的限制。公司不承担更新或修订任何前瞻性声明的意图或义务，也不解释后续实际事件与这些前瞻性声明之间的任何重大差异，除非适用法律要求。</p>
</div><p><em>Neither the Exchange nor its Regulation Services Provider (as that term is defined in policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.</em></p>
<div class="lb-trans"><p><em>交易所及其监管服务提供者（根据交易所政策定义的术语）对本公告的充分性或准确性不承担责任。</em></p>
</div><p>SOURCE Devonian Health Group Inc.</p>
<div class="lb-trans"><p>来源：Devonian Health Group Inc.</p>
</div>

DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT | DVHGF Stock News

StockTitan

Denali Therap

AMPLITECH GROUP INC. C/WTS 19/02/2026(TO PUR COM)

泥盆纪公司任命 Dennis Turpin 为首席财务官，并提供有关股票期权授予的最新信息 | DVHGF 股票新闻